financetom
Business
financetom
/
Business
/
Neurocrine's schizophrenia drug meets main goal in mid-stage study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neurocrine's schizophrenia drug meets main goal in mid-stage study
Aug 29, 2024 9:18 AM

Aug 28 (Reuters) -

Neurocrine Biosciences ( NBIX ) said on Wednesday its

experimental drug to treat adults with schizophrenia met the

main goal in a mid-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj

Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved